Form 4: Redmile Group Increases Stake in ADC Therapeutics Through Open Market Purchases

Redmile Group, along with related entities, has increased its holdings in ADC Therapeutics through a series of open market purchases of common shares.

Summary

• Redmile Group, LLC, along with related entities, including RedCo II Master Fund, L.P., and Jeremy Green, have reported purchasing additional shares of ADC Therapeutics SA.
• The transactions occurred on December 11, 2024, and involved the acquisition of 50,000 shares at a weighted average price of $2.28 and another 50,000 shares at a weighted average price of $3.81.
• These purchases increased Redmile's indirect holdings to 15,666,731 shares and direct holdings to 13,145,712 shares.
• The purchases were made within a six-month period of deemed sales reported on December 6, 2024, but at higher prices, resulting in no profits under Section 16(b) of the Securities Exchange Act.

Sentiment

Score: 7

Explanation: The document indicates increased investment by a major shareholder, which is generally a positive sign. However, the purchases were made within a short period of previous sales, which could raise some concerns, but the higher purchase price mitigates this.

Positives

• Redmile Group's increased investment suggests confidence in ADC Therapeutics.
• The purchases at higher prices than previous sales indicate a positive outlook on the company's future performance.

Risks

• The document notes that the purchases were made within six months of deemed sales, which could raise questions about short-term trading strategies, although no profits were made.
• The weighted average purchase prices indicate price volatility in the stock.

Management Comments

• Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein.
• This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

This filing reflects the ongoing investment activity of institutional investors in the biotechnology sector, specifically in companies like ADC Therapeutics that are developing novel therapies.

Comparison to Industry Standards

• Form 4 filings are a standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies.
• The reported transactions are typical for investment firms like Redmile Group, which actively manage their portfolios.
• The price ranges of $2.165 to $2.4 and $3.64 to $3.9 for the purchases indicate the stock's volatility, which is not uncommon for biotech companies.

Stakeholder Impact

• The increased investment by Redmile Group could be viewed positively by shareholders, potentially increasing confidence in the company.
• The transactions may also influence the trading volume and price of ADC Therapeutics shares.

Key Dates

Keywords

ADC Therapeutics, Redmile Group, Share Purchase, Beneficial Ownership, Jeremy Green, RedCo II Master Fund, Open Market Purchase, Section 16